Last reviewed · How we verify

Broxuridine — Competitive Intelligence Brief

Broxuridine (bromodeoxyuridine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: broxuridine. Area: Oncology.

discontinued broxuridine Thymidine kinase, cytosolic, Thymidylate kinase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Broxuridine (bromodeoxyuridine) — National Cancer Institute (NCI). Broxuridine works by mimicking the structure of thymidine, a building block of DNA, and inhibiting the enzyme thymidine kinase, which is necessary for DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Broxuridine TARGET bromodeoxyuridine National Cancer Institute (NCI) discontinued broxuridine Thymidine kinase, cytosolic, Thymidylate kinase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (broxuridine class)

  1. · 1 drug in this class
  2. National Cancer Institute (NCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Broxuridine — Competitive Intelligence Brief. https://druglandscape.com/ci/bromodeoxyuridine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: